Vivozon Healthcare, Inc. announced that it expects to receive KRW 10 billion in funding from Korea Fixed Income Investment Advisory Co., Ltd.
May 09, 2021
Share
Vivozon Healthcare, Inc. announced that it will issue series 19 non-guaranteed private equity convertible bonds for gross proceeds of KRW 10,000,000,000 to existing investor Korea Fixed Income Investment Advisory Co., Ltd. on May 10, 2021. The bonds will have surface interest of 2% per annum payable quarterly and interest to maturity of 4%. The bonds will be issued at par and matures on July 14, 2024. The bonds are convertible into 6,535,947 shares representing 4.09% stake at a fixed conversion price of KRW 1,530 per share from July 14, 2022 to June 14, 2024. The bonds are redeemable from January 14, 2023 to April 14, 2024 at premium. The expected payment date is July 14, 2021. The transaction is approved by the board of directors of the company. The securities issued are subjected to one year holding period.
Vivozon Pharmaceutical Co Ltd , formerly Vivozon Healthcare Inc, is a Korea-based company mainly engaged in the manufacture and sale of finished pharmaceutical products. The Company operates its business through three segments. The Pharmaceutical Business segment is engaged in the manufacture and sale of finished medicines such as external skin preparations, antipyretic analgesic, anti-inflammatory drugs and antidiabetic drugs. The Optical Business segment is engaged in the manufacture and sale of finished products and lighting module sets such as general lighting and automotive lighting using light emitting diode (LED) light sources. The Cosmetics Business segment is engaged in the manufacture and sale of cosmetics and cosmetic ingredients.
VIVOZON PHARMACEUTICAL CO., LTD. 
